EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy

Harry D Bear, Xiaoyan Deng, Dipankar Bandyopadhyay, Michael Idowu, Taylor M Jenkins, Maciej Kmieciak, Monique Williams, Giovanni Archer, Lindsey Gwaltney, Patrick Dillon, Daniel Flora, Daniel Stover und 9 weitere

Journal for ImmunoTherapy of Cancer · 2025-02 · 13 (2) · e010294

DOI: 10.1136/jitc-2024-010294 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 27.02.2025. Verfasst von Harry D Bear und 20 weiteren Autor:innen. Beteiligte Einrichtung: Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA hdbear@vcu.edu. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, MSD Sharp and Dohme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Higher levels of tumor-infiltrating lymphocytes (TILs) in breast cancers are associated with increased likelihood of pathologic complete response (pCR) to chemotherapy. DNA methyltransferase inhibitors (DNMTi) can augment immune responses to cancers, decreasing myeloid-derived suppressor cells (MDSCs) and increasing T lymphocyte responsiveness. We have shown that the DNMTi decitabine augments the effectiveness of immunotherapy using murine triple-negative breast cancer (TNBC) models. The primary objective was to determine whether DNMTi+immune checkpoint blockade would increase stromal TIL (sTIL) in primary breast cancers before neoadjuvant chemotherapy (NCT).

Methods

In a phase 2 study ( NCT02957968 ), patients with human epidermal growth factor receptor 2-negative breast cancer received window immunotherapy—decitabine (15 mg/m 2 ×4 doses over 5 days) followed by 2 doses of pembrolizumab (200 mg, 2 weeks apart)—before starting NCT. Biopsies before and after window immunotherapy quantified TILs and programmed death-ligand 1 (PD-L1) expression. Patients proceeded to NCT and tumor resection per standard of care. Mid-study, results of the KEYNOTE 522 trial led to patients with TNBC receiving additional pembrolizumab concurrently with standard NCT and in the adjuvant setting.

Results

46 patients (median age 54.5 years, range 28–72; 71.7% white, 28.3% black; 100% female) were treated. 21 patients had TNBC and received neither neoadjuvant pembrolizumab concurrently with NCT nor adjuvant pembrolizumab (Cohort A), 7 patients had TNBC and did receive concurrent and/or adjuvant pembrolizumab (Cohort A2), and 18 patients were estrogen receptor positive and/or progesterone receptor positive and received neither concurrent nor adjuvant pembrolizumab (Cohort B). Blood samples collected after decitabine administration before pembrolizumab showed a 59% decrease (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsDecitabineBreast NeoplasmsHumansFemaleMiddle AgedErb-b2 Receptor Tyrosine KinasesAdultAgedLymphocytes, Tumor-InfiltratingDNA Methylation

Stichwörter der Autor:innen

Breast CancerNeoadjuvant

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsErb-b2 Receptor Tyrosine KinasesDecitabinepembrolizumabERBB2 protein, human

Autor:innen und Institutionen

  • Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA hdbear@vcu.edu.
  • Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.
  • University of Virginia Cancer Center, Charlottesville, Virginia, USA.
  • St Elizabeth Healthcare, Edgewood, Kentucky, USA.
  • The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
  • Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • MSD Sharp and Dohme
  • Commonwealth Foundation for Cancer Research Foundation

Zitieren

APA

Bear, H. D., Deng, X., Bandyopadhyay, D., Idowu, M., Jenkins, T. M., Kmieciak, M., Williams, M., Archer, G., Gwaltney, L., Dillon, P., Flora, D., Stover, D., Poklepovic, A. S., Hackney, M., Ross, M., Vachhani, H., Louie, R., McGuire, K. P., Grover, A., …, & Hendrix, A. (2025). T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy. Journal for ImmunoTherapy of Cancer, 13(2), e010294. https://doi.org/10.1136/jitc-2024-010294

Vancouver

Bear HD, Deng X, Bandyopadhyay D, Idowu M, Jenkins TM, Kmieciak M, et al. T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy. Journal for ImmunoTherapy of Cancer. 2025;13(2):e010294. doi:10.1136/jitc-2024-010294

BibTeX
@article{Bear2025,
  author = {Bear, Harry D and Deng, Xiaoyan and Bandyopadhyay, Dipankar and Idowu, Michael and Jenkins, Taylor M and Kmieciak, Maciej and Williams, Monique and Archer, Giovanni and Gwaltney, Lindsey and Dillon, Patrick and Flora, Daniel and Stover, Daniel and Poklepovic, Andrew S and Hackney, Mary and Ross, Masey and Vachhani, Hetal and Louie, Raphael and McGuire, Kandace P and Grover, Amelia and Rahman, Tasnim and Hendrix, Amber},
  title = {T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {2},
  pages = {e010294},
  doi = {10.1136/jitc-2024-010294}
}
Kostenlos starten →